24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Compugen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:43
EU approves Nvidia’s $700M acquisition of Israeli startup Run:ai
21:16
Nervio appoints Dr. Richard Vogel as US CEO
19:06
Paragon’s $900M sale in limbo as Defense Ministry steps in
15:05
Full list of Israeli high-tech funding rounds in 2024
More stories
Buzz
Most popular
Daily
Weekly
1
Israeli tech’s top 10 funding rounds of 2024: Wiz sets another record
2
EU approves Nvidia’s $700M acquisition of Israeli startup Run:ai
3
Boomi acquires Israeli data management startup Rivery in $100M deal
4
The Wiz of GenAI security? “Lasso has the potential to be a once-in-a-decade company in cyber”
5
Decart raises $32M in second funding round in two months, aims to rival OpenAI and Anthropic
More news
Compugen
5 stories about Compugen
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Compugen Falls 17% on Employee Cuts Announcement
27.02.19
|
Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen
12.10.18
|
Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering
17.06.18
|
Dror Reich
The Israel-based cancer immunotherapy company intends to use the proceedings for product development
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18
|
Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen
Please ensure Javascript is enabled for purposes of
website accessibility